MedPath

Nanjing IASO Biotechnology Co.,Ltd.

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

UB-VV400 in Combination with Rapamycin in Relapsed or Refractory B-cell Malignancies

Phase 1
Not yet recruiting
Conditions
Large B-cell Lymphoma
Interventions
Genetic: UB-VV400
Drug: Rapamycin
First Posted Date
2024-12-20
Last Posted Date
2024-12-20
Lead Sponsor
Nanjing IASO Biotechnology Co., Ltd.
Target Recruit Count
70
Registration Number
NCT06743503

A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)

First Posted Date
2024-06-18
Last Posted Date
2024-06-18
Lead Sponsor
Nanjing IASO Biotechnology Co., Ltd.
Target Recruit Count
240
Registration Number
NCT06464991
Locations
🇨🇳

Peking Union Medical College Hospital, Beijing, China

🇨🇳

Peking University Third Hospital, Beijing, China

🇨🇳

People's Hospital of Peking University, Beijing, China

and more 23 locations

A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Phase 1
Recruiting
Conditions
Relapsed/Refractory Multiple Myeloma
Plasma Cell Leukemia
Interventions
Drug: CAR-T (CAR-GPRC5D)
First Posted Date
2023-03-08
Last Posted Date
2023-10-24
Lead Sponsor
Nanjing IASO Biotechnology Co., Ltd.
Target Recruit Count
12
Registration Number
NCT05759793
Locations
🇨🇳

Ruijin Hospital Affiliated with Shanghai Jiao Tong University School of Medicine, Shanghai, China

A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

Phase 1
Not yet recruiting
Conditions
Multiple Myeloma
Interventions
Drug: Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)
First Posted Date
2023-01-26
Last Posted Date
2023-01-26
Lead Sponsor
Nanjing IASO Biotechnology Co., Ltd.
Target Recruit Count
12
Registration Number
NCT05698303
Locations
🇺🇸

The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)

Phase 1
Not yet recruiting
Conditions
Multiple Myeloma
Interventions
Drug: Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)
First Posted Date
2022-01-06
Last Posted Date
2022-01-06
Lead Sponsor
Nanjing IASO Biotechnology Co., Ltd.
Target Recruit Count
20
Registration Number
NCT05181501
Locations
🇨🇳

Jiangsu Province Hospital, Nanjing, Jiangsu, China

🇨🇳

Anhui Provincial Cancer Hospital, Hefei, Anhui, China

🇨🇳

The First People's Hospital of Changzhou, Changzhou, Jiangsu, China

and more 1 locations

A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Phase 1
Not yet recruiting
Conditions
B-cell Non-Hodgkin's Lymphoma
Interventions
Drug: Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell Injection
First Posted Date
2021-10-25
Last Posted Date
2021-10-25
Lead Sponsor
Nanjing IASO Biotechnology Co., Ltd.
Target Recruit Count
125
Registration Number
NCT05091541

A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)

Phase 1
Conditions
Multiple Myeloma
Interventions
First Posted Date
2021-10-04
Last Posted Date
2021-11-23
Lead Sponsor
Nanjing IASO Biotechnology Co., Ltd.
Target Recruit Count
132
Registration Number
NCT05066646
Locations
🇨🇳

The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China

🇨🇳

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

🇨🇳

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

and more 11 locations
© Copyright 2025. All Rights Reserved by MedPath